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Background: Introduction of potent antiretro-
viral combination therapy (ART) has reduced
overall morbidity and mortality amongst HIV-
infected adults. Some prophylactic regimes against
opportunistic infections can be discontinued in
patients under successful ART. 
Questions under study: (1) The influence of the
availability of ART on incidence and mortality of
disseminated M. avium Complex infection (MAC).
(2) The safety of discontinuation of maintenance
therapy against MAC in patients on ART.
Setting: The Swiss HIV-Cohort Study, a
prospective multicentre study of HIV-infected
adults. 
Methods: Patients with a nadir CD4 count
below 50 cells/mm3 were considered at risk for
MAC and contributed to total follow-up time for
calculating the incidence. Survival analysis was
performed by using Kaplan Meier and Cox pro-
portional hazards methods. Safety of discontinua-
tion of maintenance therapy was evaluated by re-
view of the medical notes.
Results: 398 patients were diagnosed with
MAC from 1990 to 1999. 350 had a previous CD4
count below 50 cells/mm3. A total of 3208 patients
had a nadir CD4 count of less than 50 cells/mm3
during the study period and contributed to a total
follow-up of 6004 person-years. The incidence
over the whole study period was 5.8 events per 100
person-years. In the time period of available ART
the incidence of MAC was significantly reduced
(1.4 versus 8.8 events per 100 person-years, p
<0.001). Being diagnosed after 1995 was the most
powerful predictor of better survival (adjusted
hazard ratio for death: 0.27; p <0.001). None of 24
patients discontinuing maintenance therapy while
on ART experienced recurrence of MAC during 
a total follow-up of 56.6 person-years (upper 95%
confidence limit 5.3 per 100 person-years).
Conclusion: Introducing ART has markedly re-
duced the risk of MAC for HIV-infected individ-
uals with a history of very low CD4 counts. Sur-
vival after diagnosis of MAC has improved after
ART became available. In patients responding 
to ART, discontinuation of maintenance therapy
against M. avium may be safe.
Key words: M. avium Complex; human immuno-
deficiency virus; antiretroviral combination therapy;
incidence; survival; prognosis; discontinuation of main-
tenance therapy; secondary prophylaxis; cohort study
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Summary
Introduction 
Disseminated infection with M. avium Com-
plex (MAC) is a frequent late complication of HIV-
infection. During the natural course of HIV-in-
fection up to 15% of patients will suffer from this
opportunistic infection (OI) within 12 months
after their CD4 count has fallen below 50
cells/mm3 [1–3]. New regimes for treatment and
primary prophylaxis were evaluated and proved
beneficial in the early 1990’s [4]. Nevertheless, in-
cidence of MAC rose until 1993 (Figure 1) and the
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Patients and methods
The Swiss HIV Cohort Study (SHCS)
The SHCS enrols HIV-infected persons aged 16
years or older [17]. Patients are followed up in one of seven
study centres. Enrolment is independent of disease stage
and degree of immunodeficiency. Data are collected ac-
cording to standardised criteria on structured forms at
registration and at follow-up visits scheduled at 6 months
intervals. AIDS is defined according to category C clini-
cal conditions of the Centers for Disease Control and Pre-
vention classification system for HIV infection (revised in
1993) [18]. Informed consent is obtained from all partici-
pants. The SHCS is representative for the epidemiology
of advanced HIV-infection in Switzerland and includes
approximately 70% of the patients diagnosed with AIDS
in the country [19]. More detailed information is available
online on http://www.shcs.ch.
Analysis of incidence and survival rates of patients
with disseminated M. avium infection
Patients with disseminated M. avium infection diag-
nosed between January 1990 and December 1999 were in-
cluded in the analysis. According to the SHCS definition,
diagnosis requires M. avium to have been cultured from
tissue samples other than sputum, stool or skin and a con-
current illness consistent with the diagnosis, eg, weight
loss, fever, diarrhoea or anaemia. 
Incidence rate of MAC: Incidence density of dissemin-
ated M. avium infection was calculated year-wise by divid-
ing the numbers of SHCS participants developing dissem-
inated M. avium infection by the total follow-up time in the
SHCS of all patients at risk. Only the first diagnosis of MAC
in each patient was included. Since disseminated M. avium
infection occurs nearly exclusively in patients with a CD4
cell count below 50cells/mm3 only patients with former
counts below this level contributed to the follow-up time.
Patients with disseminated M. avium infection without a
CD4 count measurement below 50 cells/mm3 before diag-
nosis were not included in the calculation of incidence. Po-
tent ART was introduced in the SHCS during 1996, and all
patients had potential access to this treatment that was paid
for by the obligatory health insurances. From 1997
onwards, antiretroviral treatment with at least 3 drugs was
the most often prescribed regime (figure 1). Therefore, to
assess influence of the availability of ART on disseminated
M. avium infection, overall incidence from 1990 to 1996 
was compared to the incidence thereafter. This ecological
approach was chosen because it better represents the influ-
ence of the availability of ART on a population basis, than
just comparing patients who did and did not receive ART.
The latter type of comparison always leads to biased results,
because those patients prescribed and taking ART differ
sociodemographically from those that are not [20]. 
Survival: Patients within the SHCS that were diag-
nosed with disseminated M. avium infection in 1996 or
later had access to potent ART with a protease-inhibitor
based three drug regimen. To assess the influence of po-
tent ART on mortality, we compared survival rates of pa-
tients with MAC before and after 1996. Patients with the
diagnostic procedure at the day of death or with a post-
mortem diagnosis were excluded from the survival analy-
sis. Cox proportional hazards regression model including
time-period of diagnosis of MAC, quartile of CD4 cell
count at diagnosis, sex, age and transmission mode was
performed to obtain the adjusted hazard ratio for the time-
period. The real introduction of ART and the treatment
of MAC for a single patient was not included in the model,
because the time gap of drawing blood cultures for MAC
and the results from cultures is usually several weeks.
Therefore, patients with an a priori better prognosis,
namely surviving at least 6 weeks, would have started these
treatments with a greater probability. This would have bi-
ased the results of the model regarding these variables. In
addition, as mentioned above, patients on potent ART dif-
fer sociodemographically from those who are not, in a
manner that is difficult to correct for. 
Interruption of maintenance therapy against
disseminated M. avium infection
The patients with a history of disseminated M. avium
infection who stopped their maintenance therapy while on
ART were identified within the SHCS database. A struc-
tured review of the records was undertaken for all of these
patients: clinical and laboratory data at the time of diagno-
sis of MAC, at the time of starting ART, at the time of dis-
continuation maintenance therapy, and at the last follow-up
visit were obtained. Incidence (with corresponding 95%
confidence limits) of recurrence after discontinuation was
survival of patients with disseminated M. avium
infection did not improve until 1996 in the Swiss
HIV Cohort Study (SHCS) [3]. 
However, introduction of potent antiretroviral
combination therapy (ART) in 1996 changed the
natural history of HIV-infection. Patients on ART
experience restoration of their immune system and
have a lower risk of opportunistic infections there-
after [5, 6]. This decline in incidence may occur
within the first three months of ART for some OIs,
but for disseminated M. avium infection a signifi-
cant reduction in risk is found only after 6 to 9
months of successful ART [7].
While mortality is markedly reduced in pa-
tients on ART, the effect on survival in patients hav-
ing experienced serious specific late stage oppor-
tunistic infections is at present less well analysed.
Many physicians care for patients surviving long
term after having disseminated M. avium infection.
In these patients it has to be decided whether main-
tenance therapy against recurrence of MAC is
needed lifelong. Since primary prophylaxis against
MAC and other opportunistic infections may be
discontinued in patients with a sustained increase
of their CD4 count [8–13] and discontinuation of
maintenance therapy against P. carinii pneumonia
and cytomegalovirus retinitis may be safe in certain
circumstances [14, 15], some physicians and pa-
tients tend to interrupt maintenance therapy
against M. avium, despite the limited evidence on
the safety of this discontinuation [12, 16]. 
In the SHCS we addressed the issues of inci-
dence and survival of disseminated M. avium infec-
tion before and in the era of ART, and the course
of patients who interrupted maintenance therapy.
calculated by using the time period from discontinuation to
the last follow-up or to the date of recurrence as a denom-
inator and by assuming a Poisson distribution of events.
Statistical analyses included calculation of incidences
with confidence intervals assuming a Poisson distribution
of events, survival analyses using the Kaplan-Meier life-
table method assessing the equality of the survival func-
tion by the log-rank test and Cox proportional hazards re-
gression model. The proportional hazards assumptions
were tested using Schoenfeld residuals. Non-parametric
Wilcoxon rank sum test was used for comparison of nu-
merical data between two unrelated groups. Stata software
(version 7; Stata Corporation, College Station, Texas,
USA) was used.
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Results
From 1990 to 1999 398 patients were diag-
nosed with disseminated M. avium infection
within the SHCS. Distribution regarding gender
(22% female) and transmission mode (39% men
who had sex with men, 38% intravenous drug use,
21% heterosexual and 2% others) reflect the epi-
demiology of HIV-infection in the SHCS and in
Switzerland. The median age and the correspon-
ding interquartile range (IQR) was 34 years (IQR
30–40) and the median CD4 cell count at diagno-
sis was 10 cells/mm3 (IQR 2–20). There was no sta-
tistically significant difference in age or CD4 count
at diagnosis between the 320 patients diagnosed
before 1996 and the 78 diagnosed thereafter.
Incidence
350 (88%) patients with disseminated M.
avium infection had a CD4 count below 50
cells/mm3 measured before diagnosis. They were
included in the calculation of incidence. A total of
3208 patients had a nadir CD4 count of less than
50 cells/mm3 during the studied period and con-
tributed to a total follow-up of 6004 person-years.
Of these 3208 patients 24% percent were female,
and transmission mode was men who had sex with
men in 36%, intravenous drug use in 37%, hete-
rosexual in 23% and others in 4%. The incidence
over the whole study period was 5.8 events per 100
person-years. The incidence per year is shown in
figure 1. From 1990 until the end of 1996 during
a total follow-up time of 3563 person-years, there
were 315 episodes of disseminated M. avium in-
fection resulting in an incidence of 8.8 per 100 per-
son-years (95% confidence interval 7.9–9.8) com-
pared to 35 cases during a total follow-up time of
2441 person-years (incidence 1.4 per 100 person-
Figure 1
Use of antiretroviral
drug regimes within
the Swiss HIV Cohort
Study (top panel) and
incidence density of
disseminated M.
avium Complex
infection (cases per
100 person-years) in
patients with a nadir
CD4 cell count below
50 cells per mm3
from 1990 to 1999
(bottom panel). 
The percentages of
patients on at least 
3 antiretroviral drugs
were 13% in the
middle of 1996, 48%
in the middle of 1997,
65% in the middle of
1998, and 71% in the
middle of 1999. The
respective percent-
ages for patients with
a nadir CD4 count
below 50 cells per
mm3 were 55%
(1996), 75% (1997),
80% (1998), and 84%
(1999).
years; 95% CI 1.0–1.9) from 1997 until 1999. This
corresponds to a decrease in incidence of 7.4 per
100 person-years (95% CI 6.3–8.4) or an incidence
ratio of 0.16 (95% CI 0.11–0.23) which is highly
significant (p <0.001). The highest incidence was
observed in 1993 with a rate of 13.7 events per 100
person-years (95% CI 10.7–17.3), whereas the
lowest incidence was 0.73 events per 100 person-
years (95% CI 0.26–1.5) in 1998.
Survival
Twenty patients (5%) were excluded from the
survival analysis because diagnosis of disseminated
M. avium infection was made at the day of death
or post-mortem. All these patients were diagnosed
before 1996. 378 patients were thus included in the
survival analysis. Figure 2 shows Kaplan Meier es-
timates of survival after diagnosis of disseminated
M. avium infection in 300 patients diagnosed be-
fore 1996 compared to 78 that were diagnosed
from 1996 to 1999. Survival improved significantly
(p <0.001 by log rank test) after introduction of po-
tent ART. A Cox proportional hazards model in-
cluding time period of diagnosis, sex, transmission
mode, quartile of CD4 count at diagnosis and age
was used to look at and correct for confounding
factors. In this model the time period of diagnosis
(1996–1999 versus 1990–1995) remained the most
powerful predictor for survival (table 1).
Interruption of maintenance therapy
The 24 patients who had interrupted mainte-
nance therapy were identified using the SHCS
database. Baseline and follow-up characteristics of
these patients are shown in table 2. Stopping sup-
pression therapy was proposed by the treating
physicians of 12 patients. Another ten patients
wished themselves to cease therapy, in two cases
the reason for stopping could not be determined. 
Figure 3 shows the absolute CD4 cell count
values during follow-up of the patients discontin-
uing maintenance therapy.
During the observed period of 56.6 person-
years, no recurrences of MAC were clinically doc-
umented. In addition, negative control blood cul-
tures confirmed absence of M. avium Complex
bacteraemia in eleven patients. The median fol-
low-up time was 29 months (range 11 to 50
months). The upper 95% confidence level of inci-
dence was 5.3 events per 100 person-years.
Two patients died during the follow-up period.
One patient with end stage liver cirrhosis due to hep-
atitis C had a fatal pneumonia and one patient died
of an invasive bacteraemic infection with S. aureus.
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Figure 2
Kaplan Meier curve
of survival after diag-
nosis with disse-
minated M. avium
Complex infection in
AIDS patients en-
rolled in the Swiss
HIV Cohort Study
according to the time
period of availability
of potent antiretrovi-
ral combination the-
rapy. These regimen
were not available
before 1996.
Discussion
Introduction of antiretroviral combination
therapy has markedly changed the natural history of
HIV-infection in developed countries. Morbidity
and mortality have declined [5, 6]. 
Disseminated M. avium infection is a typical op-
portunistic infection occurring mainly in stages of
profound immunodeficiency during HIV-infection
[1, 3, 21] as shown by the median CD4 count of only
10 cells/mm3 at baseline in the current analysis of
the SHCS. Median survival after this opportunistic
infection has been below one year even after intro-
duction of antimycobacterial combination
chemotherapy including newer macrolides in the
mid nineties [2, 3, 22–25].
Primary prophylaxis against MAC with
azithromycine, clarithromycine or rifabutin has
proven beneficial in patients at high risk for this
complication indicated by CD4 counts below 50
cells/mm3 [4, 26, 27]. However, primary prophylaxis
against MAC has not been widely used within the
SHCS [8]. Despite only moderate efficacy of about
50% risk reduction [27], availability of this prophy-
laxis after 1993 could explain in part the subsequent
decline of the incidence rate of MAC in the SHCS. 
The risk of MAC in an individual patient with
low CD4 counts remains high during the first three
months of ART and declines sharply thereafter if
the CD4 count rises to above 100 cells/mm3 [7], al-
lowing withdrawal of antimycobacterial prophylaxis
against this pathogen [8, 10, 28]. On a population
level the present analysis shows that during the time
period when ART became available, there was a
major influence on the incidence of MAC. Our re-
sults are in concordance with the recently published
analysis of the EuroSIDA cohort which demon-
strated that the risk of disseminated MAC decreased
with increasing calendar time after 1995 [29]. 
One might argue that the incidence declined
because the risk of exposure to this pathogen de-
creased during the same period. Since M. avium is
an ubiquitous micro-organism there is no evidence
for such a bias [30]. In addition the laboratory meth-
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Parameter Crude hazard ratio Adjusted hazard ratio*
(95% CI) (95% CI)
Time period of diagnosis (1996–1999 versus 1990–1995) 0.29 (0.20–0.41) 0.27 (0.18–0.39)
p <0.001 p <0.001
CD4 count quartile (per quartile increase)** 0.92 (0.83–1.03) 0.89 (0.81–0.99)
p = 0.16 p = 0.04
Female sex 0.79 (0.61–1.04) 0.98 (0.71–1.34)
p = 0.1 p = 0.9
Transmission risk group as compared to MSM
Heterosexual 0.72 (0.53–0.98) 0.86 (0.60–1.23)
p = 0.04 p = 0.9
IDU 0.858 (0.62–1.15) 1.05 (0.79–1.40)
p = 0.2 p = 0.7
Others 0.78 (0.33–1.79) 0.82 (0.40–1.70)
p = 0.5 p = 0.6
Age quartile (per quartile increase) 1.08 (0.98–1.19) 1.11 (0.99–1.25)
p = 0.13 p = 0.07
* adjusted for all the variables listed 
** CD4 count quartiles represent the studied population stratified by CD counts, the first quartile is the quarter of the studied
population with the lowest CD4 counts, the second quartile the quarter of the population with CD4 counts between the 25th
percentile and the median and so on. The CD4 at the respective quartile limits are described in the results section.
Table 1
Hazard ratio of death
according to a Cox
proportional hazards
regression model in
378 patients with a
diagnosis of dissemi-
nated M. avium
infection.
Diagnosis start ART stop MAC- last 
of MAC suppression follow-up
Age 32 (22–50)
Weight (kg) 60 (43–74) 58 (43–74) 65 (48–76) 67 (48–81)
Haemoglobin (g/l) 98 (64–134) 103 (81–139) 129 (99–150) 142 (100–181)
CD4 Cell Count cells/mm3 11 (0–304) 14 (2–315) 127 (27–644) 291 (1–740)
Percentage of CD4 cells of total lymphocyte count 3 (0–23) 4 (1–29) 14 (3–29) 18 (1–33)
HIV RNA (log10 copies/ml) 5.3 (2.3–6.4) 5.7 (0.6–6.3) 3.6 (0.6–5.9) 2.6 (0.6–6.0)
Table 2
Characteristics and
follow-up data of 24
patients who discon-
tinued maintenance
therapy against 
M. avium (median,
range).
Figure 3
Absolute CD4 counts
of 24 patients discon-
tinuing maintenance
therapy against M.
avium.
ods for culture and identification of mycobacteria
have improved within the last ten years and physi-
cians are still well aware of the clinical presentation
of MAC making detection bias highly improbable. 
ART results in restitution of specific memory
immune response against pathogens to which pa-
tients are chronically exposed [31–34]. This may
lead to marked inflammatory responses within a few
weeks after starting ART [35–39]. M. avium is a
micro-organism with low virulence but leads to high
bacterial burden in disseminated disease. There-
fore, in addition to antimycobacterial drugs an even
moderately strengthened immune system will prob-
ably be important to overcome chronic progressive
infection and disease. In fact, there are AIDS pa-
tients recovering from M. avium bacteremia who
have only started ART, without the need for addi-
tional antimycobacterial drugs [40]. 
In the present analysis, being diagnosed with
disseminated MAC during the period after potent
ART became available is an impressively strong pre-
dictor of a better survival. Median survival of dis-
seminated MAC changed from about seven months
before 1996 to more than four years thereafter. The
ecological population based approach of including
the availability of ART instead of successful anti-
retroviral treatment as a parameter in the model of
survival is a conservative one. The real effect of tak-
ing ART may be still stronger. In fact, patients di-
agnosed after 1995 who never started potent ART
had a median survival of less than seven months.
However, given the imminent biases of comparisons
of patients on ART to those not on ART, the cho-
sen strategy of analysis is the one closest to an in-
tention to treat approach. 
Until recently there was little evidence sup-
porting the discontinuation of maintenance therapy
against opportunistic infections [12]. However,
more and more observational studies describe suc-
cessful interruption of secondary prophylaxis
against eg, P.carinii or cytomegalovirus [13]. Given
the relatively low virulence of M. avium such an ap-
proach should be possible in disseminated M. avium
infection once a certain immune-restitution has
taken place [16]. Discontinuation is still more ap-
pealing taking into account the side effects, costs
and global resistance driving forces of antimyco-
bacterial combination therapy.
In the current analysis we identified no recur-
rence of MAC disease in patients who had stopped
taking maintenance therapy against MAC while on
ART. The upper confidence limit for incidence of
recurrence of more than 5 per 100 person-years,
however, precludes from stating that this approach
is very safe. In addition, retrospective review of
medical records for analysis of prospectively col-
lected cohort data does not allow definition of a
CD4 threshold level above which stopping mainte-
nance therapy can be considered as safe. The
median CD4 count at the time of discontinuation
was slightly above 100 cells/mm3 in the patients
studied. However, the group of patients that inter-
rupted therapy was very heterogenous and included
four patients with a CD4 count of less than
50cells/mm3. A sustained increase to at least 100
cells/mm3 has proven safe for stopping primary pro-
phylaxis [8]. It might well be a valuable threshold
level for discontinuing maintenance therapy.
In conclusion, introduction of potent antiretro-
viral combination therapy has markedly reduced the
risk of disseminated MAC infection for HIV-in-
fected individuals with a history of very low CD4
counts. Furthermore, survival after a diagnosis of
disseminated MAC infection has improved since
antiretroviral combination therapy became avail-
able. In patients surviving this disease and respond-
ing to antiretroviral treatment, discontinuation of
maintenance therapy against M. avium seems to be
possible and should be studied prospectively.
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Appendix
The members of the Swiss HIV Cohort Study
are M. Battegay (Chairman of the Scientific Board),
E. Bernasconi, H. Bucher, Ph. Bürgisser, M. Egger,
P. Erb, W. Fierz, M. Flepp (Chairman of the Clin-
ical and Laboratory Committee), P. Francioli (Pres-
ident of the SHCS, Centre Hospitalier Universi-
taire Vaudois, CH-1011 Lausanne), H. Furrer, M.
Gorgievski, H. Günthard, P. Grob, B. Hirschel, Th.
Klimkait, B. Ledergerber, M. Opravil, F. Paccaud,
G. Pantaleo, L. Perrin, J.-C. Piffaretti, M. Ricken-
bach (Head of Data Center), C. Rudin, P. Sudre, V.
Schiffer, J. Schupbach, A. Telenti, P. Vernazza, Th.
Wagels, R. Weber
Correspondence:
Hansjakob Furrer, MD
Divison of Infectious Diseases
University Hospital
Inselspital PKT2B
CH–3010 Bern
e-mail: hansjakob.furrer@insel.ch
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